Appointed
James B. Frakes
Chief Executive Officer
AEMD ·
AETHLON MEDICAL INC
appointed James B. Frakes to serve as the Company’s permanent Chief Executive Officer
Ready 8-Ks
34
Latest filing
June 4, 2026, 9:00 AM ET
Top materiality
0.80
Event mix
other_material ×21 · earnings ×8 · regulatory ×3
Sentiment
6 pos · 1 neg · 27 neu
Latest earnings
reported 2026-Q3
Executive change
recent →
Recent 8-K filings for AEMD
Highest-materiality recent filing
Aethlon Medical receives Nasdaq delisting notice for bid price below $1.00, requests hearing, implements reverse split
- Received Nasdaq notice on Oct 16, 2025 for non-compliance with minimum bid price of $1.00 over 30 consecutive business days.
- Company requested a hearing before Nasdaq Hearings Panel, automatically staying delisting pending decision.
-
Filed Amendment No. 1 to Prospectus Supplement under S-3 Registration Statement (File No. 333-292405) on June 4, 2026.
-
Aethlon Medical discloses 1,569,110 shares outstanding after all pre-funded warrants exercised
As of March 16, 2026, Aethlon Medical has 1,569,110 shares of common stock outstanding.
-
Aethlon Medical stockholders approve increase in authorized shares to 100M and equity plan amendment
Stockholders approved increase in authorized common shares from 6M to 100M (495,950 for, 58,624 against).
-
Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY
Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.
-
Aethlon removes shareholder approval condition; pre-funded warrants immediately exercisable
Amendments to SPA and Pre-Funded Warrant remove Nasdaq 5635 shareholder approval requirement, effective Jan 22, 2026.
-
Aethlon Medical prices $3.3M PIPE and warrant inducement at $4.03/unit
Gross proceeds ~$3.3M from private placement and warrant inducement; closing expected Dec 8, 2025.
-
Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances
Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.
-
Aethlon Medical regains Nasdaq minimum bid price compliance, matter closed
Received Nasdaq letter on Nov 5, 2025 confirming regained compliance with $1.00 minimum bid price rule.
-
Received Nasdaq notice on Oct 16, 2025 for non-compliance with minimum bid price of $1.00 over 30 consecutive business days.
-
Reverse split effective 10:00 a.m. ET Oct 16, 2025; split-adjusted trading begins Oct 20 under symbol AEMD.
-
Aethlon Medical reports 7,373,156 shares outstanding after best-efforts offering
Shares outstanding: 7,373,156 as of September 12, 2025.
-
Aethlon Medical prices $4.5M public offering of common stock and warrants at $0.90/unit
Gross proceeds of $4.5M; net to company ~$3.9M after placement agent fees and expenses.
-
Aethlon Medical releases updated corporate presentation; no financial details disclosed
Updated presentation furnished as Exhibit 99.1 and available on company website.
-
Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort
Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.
-
Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.
-
Aethlon Medical set 1-for-8 reverse stock split effective June 6, 2025
Reverse split ratio: 1-for-8; effective 5:00 PM ET June 6, 2025.
-
Stockholders approved reverse split at ratio 1:5 to 1:12, board to determine timing by May 13, 2026.
-
Aethlon Medical raises ~$2.3M via warrant exercise inducement, issues new warrants
Gross proceeds of approximately $2,316,320 from exercise of 6,200,000 Existing Warrants at reduced price of $0.3736/share.
-
Aethlon Medical Q3 net loss narrows to $1.8M; first patient treated in Hemopurifier cancer trial
Cash balance $4.8M at Dec 31, 2024; operating expenses down 50% YoY to $1.8M.
-
Aethlon Medical gets 180-day Nasdaq extension through June 23, 2025 for bid price rule
Received 180-day extension from Nasdaq until June 23, 2025 to regain $1.00 minimum bid price compliance.
-
Aethlon Hemopurifier removes 99% of H5N1 in vitro; monitoring bird flu outbreak
In vitro study with scaled-down Hemopurifier showed 99% removal of H5N1 virus after 6 hours.
-
Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial
Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.
-
Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors
First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.
-
Aethlon Medical appoints James B. Frakes as permanent CEO; COO Guy F. Cipriani departs
James B. Frakes, serving as interim CEO since Nov 7, 2023, appointed permanent CEO effective Oct 3, 2024; remains CFO and Board member.
-
Shareholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 3,000,000 to total 3,364,256 shares.
-
Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024
Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
-
Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial
Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.
-
Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia
Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.
-
Aethlon Medical dismisses Baker Tilly, engages Haskell & White as new auditor
Dismissed Baker Tilly US, LLP effective July 1, 2024; audit committee approved.
-
Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved
Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.
-
Aethlon Medical reports 9,229,725 shares outstanding after public offering
Outstanding shares as of May 23, 2024 total 9,229,725, updated after a best-efforts public offering.
-
Aethlon Medical prices $4.7M public offering of common stock and warrants at $0.58 per unit
Gross proceeds ~$4.7M; net proceeds ~$3.84M after placement agent fees and expenses.
-
In vitro binding study of Hemopurifier shows removal of extracellular vesicles (EVs) directly from cancer patient plasma.
-
Aethlon Medical updates corporate presentation for April 2024; no material new details disclosed
Updated presentation made available for investor meetings; filed as Exhibit 99.1.
Executive changes
Departed
Guy F. Cipriani
Chief Operating Officer
AEMD ·
AETHLON MEDICAL INC
Guy F. Cipriani, Chief Operating Officer of the Company, has departed the Company.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.57 · Most common event other_material